Epizyme Inc. (NASDAQ:EPZM)’s share price was up 2.1% during mid-day trading on Friday . The stock traded as high as $10.03 and last traded at $9.89, with a volume of 133,457 shares trading hands. The stock had previously closed at $9.69.

Several equities analysts have recently issued reports on EPZM shares. JMP Securities reissued a “buy” rating and set a $28.00 target price on shares of Epizyme in a research note on Thursday, June 23rd. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Cowen and Company reaffirmed a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Leerink Swann reaffirmed a “buy” rating on shares of Epizyme in a research note on Tuesday, April 19th. Finally, Citigroup Inc. assumed coverage on Epizyme in a research note on Tuesday, April 5th. They issued a “buy” rating and a $17.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. Epizyme presently has an average rating of “Buy” and an average price target of $23.11.

The company’s market cap is $561.35 million. The company has a 50 day moving average of $10.97 and a 200-day moving average of $10.74.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.12. On average, analysts anticipate that Epizyme Inc. will post ($2.25) EPS for the current fiscal year.

In related news, insider Robert A. Copeland sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $10.03, for a total transaction of $40,120.00. Following the completion of the sale, the insider now directly owns 4,000 shares of the company’s stock, valued at approximately $40,120. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Several large investors have modified their holdings of EPZM. Jennison Associates LLC raised its stake in shares of Epizyme by 252.4% in the fourth quarter. Jennison Associates LLC now owns 893,913 shares of the biopharmaceutical company’s stock worth $14,320,000 after buying an additional 640,245 shares in the last quarter. Jennison Associates raised its stake in shares of Epizyme by 0.6% in the third quarter. Jennison Associates now owns 253,668 shares of the biopharmaceutical company’s stock worth $3,262,000 after buying an additional 1,551 shares in the last quarter. Finally, California Public Employees Retirement System acquired a new stake in shares of Epizyme during the fourth quarter worth about $2,723,000.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.